GlassScriptPhysician profile
Akhila Madala
NPI 1003376104
$3,054.32
in general payments reported to CMS, 2019-2025
21 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $463 · 2024: $1,374 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $654.58 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $440.62 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $437.92 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $221.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $215.94 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.51 | 2024-2025 | Jardiance, Ofev |
| Stryker Corporation | $124.43 | 2024 | Aequalis Perform |
| Glaxosmithkline, LLC. | $102.94 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.44 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $83.72 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $82.09 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $74.83 | 2023-2024 | Quviviq |
| Amgen INC. | $71.11 | 2024-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $61.84 | 2023-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $52.63 | 2025 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.98 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $38.14 | 2024-2025 | |
| Radius Health, INC. | $30.16 | 2025 | Tymlos |
| Astellas Pharma US INC | $24.34 | 2024 | Veozah |
| Edwards Lifesciences Corporation | $23.65 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Xeris Pharmaceuticals, INC. | $18.87 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akhila Madala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.